Innate Pharma (IPHA) Short Interest Ratio & Short Volume → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free IPHA Stock Alerts $2.55 +0.12 (+4.95%) (As of 05/3/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Innate Pharma Short Interest DataCurrent Short Volume81,300 sharesPrevious Short Volume76,900 sharesChange Vs. Previous Month+5.72%Dollar Volume Sold Short$196,746.00Short Interest Ratio / Days to Cover7.8Last Record DateApril 15, 2024Outstanding Shares80,860,000 sharesPercentage of Shares Shorted0.10%Today's Trading Volume3,962 sharesAverage Trading Volume9,496 sharesToday's Volume Vs. Average42% Short Selling Innate Pharma ? Sign up to receive the latest short interest report for Innate Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatIPHA Short Interest Over TimeIPHA Days to Cover Over TimeIPHA Percentage of Float Shorted Over Time Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. Innate Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202481,300 shares $196,746.00 +5.7%N/A7.8 $2.42 3/31/202476,900 shares $221,472.00 -13.7%N/A7.7 $2.88 3/15/202489,100 shares $217,404.00 +13.7%N/A7.6 $2.44 2/29/202478,400 shares $205,408.00 -4.9%N/A4.1 $2.62 2/15/202482,400 shares $212,592.00 +8.4%N/A4.7 $2.58 1/31/202476,000 shares $203,680.00 -0.9%N/A4 $2.68 Get the Latest News and Ratings for IPHA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. 1/15/202476,700 shares $214,760.00 -8.9%N/A3.7 $2.80 12/31/202384,200 shares $235,760.00 +55.9%N/A3.9 $2.80 12/15/202354,000 shares $130,140.00 -5.9%N/A2.6 $2.41 11/30/202357,400 shares $137,760.00 -4.3%N/A4.3 $2.40 11/15/202360,000 shares $147,600.00 -6.0%N/A4.2 $2.46 10/31/202363,800 shares $151,844.00 +11.5%N/A4.4 $2.38 10/15/202357,200 shares $132,418.00 -8.5%N/A5 $2.32 9/30/202362,500 shares $158,125.00 -3.4%N/A6 $2.53 9/15/202364,700 shares $192,159.00 -1.5%N/A6.7 $2.97 8/31/202365,700 shares $191,324.97 -8.1%N/A5.2 $2.91 8/15/202371,500 shares $206,635.00 -3.8%N/A6.1 $2.89 7/31/202374,300 shares $218,442.00 -1.9%N/A6.8 $2.94 7/15/202375,700 shares $244,511.00 -3.8%N/A6.4 $3.23 6/30/202378,700 shares $242,002.50 +20.0%N/A6.1 $3.08 6/15/202365,600 shares $213,856.00 +9.7%N/A4 $3.26 5/31/202359,800 shares $175,812.00 -4.3%N/A3.8 $2.94 5/15/202362,500 shares $186,875.00 No ChangeN/A3.6 $2.99 10/31/2022147,600 shares $317,340.00 +12.8%N/A12.9 $2.15 10/15/2022130,900 shares $261,800.00 +15.5%N/A12.5 $2.00 9/30/2022113,300 shares $226,600.00 +1.3%N/A12.7 $2.00 9/15/2022111,900 shares $284,226.00 +2.3%N/A13.3 $2.54 8/31/2022109,400 shares $293,192.00 +0.2%N/A6.4 $2.68 8/15/2022109,200 shares $321,048.00 -10.1%N/A5.9 $2.94 7/31/2022121,500 shares $388,787.85 -3.6%N/A6.1 $3.20 7/15/2022126,000 shares $347,760.00 +0.3%N/A4.9 $2.76 6/30/2022125,600 shares $339,120.00 +3.9%N/A4.8 $2.70 6/15/2022120,900 shares $305,877.00 +1.9%N/A4.6 $2.53 5/31/2022118,700 shares $315,742.00 -13.6%N/A6.2 $2.66 5/15/2022137,300 shares $394,051.00 +8.0%N/A6.7 $2.87 4/30/2022127,100 shares $364,777.00 -9.3%N/A5.7 $2.87 4/15/2022140,100 shares $438,513.00 +4.0%N/A6 $3.13 3/31/2022134,700 shares $452,592.00 +105.0%N/A5.3 $3.36 3/15/202265,700 shares $207,612.00 +13.9%N/A1.6 $3.16 2/28/202257,700 shares $196,757.00 -2.5%N/A1 $3.41FW: 234x Gain (Ad)This coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here. IPHA Short Interest - Frequently Asked Questions What is Innate Pharma's current short interest? Short interest is the volume of Innate Pharma shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 81,300 shares of IPHA short. Learn More on Innate Pharma's current short interest. What is a good short interest ratio for Innate Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IPHA shares currently have a short interest ratio of 8.0. Learn More on Innate Pharma's short interest ratio. Is Innate Pharma's short interest increasing or decreasing? Innate Pharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 81,300 shares, an increase of 5.7% from the previous total of 76,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Innate Pharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Innate Pharma: X4 Pharmaceuticals, Inc. (7.30%), Century Therapeutics, Inc. (6.91%), Zura Bio Limited (2.27%), Acumen Pharmaceuticals, Inc. (2.40%), Cardiff Oncology, Inc. (8.92%), Compass Therapeutics, Inc. (1.88%), Genfit S.A. (0.19%), Opthea Limited (0.21%), Elevation Oncology, Inc. (13.03%), Adverum Biotechnologies, Inc. (7.54%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Innate Pharma stock? Short selling IPHA is an investing strategy that aims to generate trading profit from Innate Pharma as its price is falling. IPHA shares are trading up $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Innate Pharma? A short squeeze for Innate Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IPHA, which in turn drives the price of the stock up even further. How often is Innate Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IPHA, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: X4 Pharmaceuticals Short Interest Century Therapeutics Short Interest Zura Bio Short Interest Acumen Pharmaceuticals Short Interest Cardiff Oncology Short Interest Compass Therapeutics Short Interest Genfit Short Interest Opthea Short Interest Elevation Oncology Short Interest Adverum Biotechnologies Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IPHA) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldThe only AI company you should be looking atBehind the MarketsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith